Exercise as an end-point in pulmonary hypertension trials

International Journal of Clinical Practice

Volumn 64, Issue SUPPL. 165, 2010, Pages 4-6

  McCullagh, B ^a   Girgis, R E ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; UNIPROST; VERAPAMIL;

CARDIOPULMONARY EXERCISE TEST; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXERCISE; HEART VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SENSITIVITY AND SPECIFICITY; ARTICLE; BIOASSAY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; ENDURANCE; EXERCISE TEST; INSTRUMENTATION; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REFERENCE VALUE; WALKING;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ENDPOINT DETERMINATION; EXERCISE TEST; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PHYSICAL ENDURANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; RESEARCH DESIGN; WALKING;

EID: 79951983814     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02231.x     Document Type: Review

References (23)

1. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000 161 (2 Pt 1 487 492.
2. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 40 : 780 788.
3. Paciocco G, Martinez FJ, Bossone E, Pielsticker E, Gillespie B, Rubinfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 2001 17 : 647 652.
4. Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma - how measuring everything measures nothing. Rheumatology (Oxford) 2008 47 : 68 9.
5. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009 36 : 330 336.
6. Gomberg-Maitland M, Huo D, Benza RL, McLaughlin VV, Tapson VF, Barst RJ. Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant 2007 26 : 732 738.
7. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002 106 : 319 324.
8. Oudiz RJ, Barst RJ, Hansen JE et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 2006 97 : 123 126.
9. Groepenhoff H, Vonk-Noordegraaf A, Boonstra A, Spreeuwenburg MD, Postmus PE, Bogard HJ. Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc 2008 40 : 1725 1732.
10. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951 11 : 686 705.
11. Provencher S, Herve P, Sitborn O, Humbert M, Simonneau G, Chemla D. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. Eur Respir J 2008 32 : 393 398.
12. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008 26 : 501 507.
13. McGregor M, Sniderman A. On pulmonary vascular resistance: the need for more precise definition. Am J Cardiol 1985 55 : 217 221.
14. Frantz RP, Benza RL, Kjellstrom B et al. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2008 27 : 780 788.
15. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 1 (Suppl 14S 34S.
16. Yeo TC, Dujardin KS, Tei C, Mahony DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998 81 : 1157 1161.
17. Forfia PR, Fisher MR, Mathal SC et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006 174 : 1034 1041.
18. Marechaux S, Pincon C, Le Tourneau T et al. Cardiac correlates of exercise induced pulmonary hypertension in patients with chronic heart failure due to left ventricular systolic dysfunction. Echocardiography 2008 25 : 386 393.
19. Umehara M, Yamaguchi A, Itakura S et al. Repeated waon therapy improves pulmonary hypertension during exercise in patients with severe chronic obstructive pulmonary disease. J Cardiol 2008 51 : 106 113.
20. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008 52 : 1683 1692.
21. Rietema H, Holverda S, Bogaard HJ et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008 31 : 759 764.
22. Stolz D, Rasch H, Linka A et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008 32 : 619 628.
23. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008 32 : 1371 1385.